相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study
Harold E. Lebovitz et al.
EXPERT OPINION ON PHARMACOTHERAPY (2022)
Advances in Oral Drug Delivery
Mohammed S. Alqahtani et al.
FRONTIERS IN PHARMACOLOGY (2021)
The promising future of insulin therapy in diabetes mellitus
Ran Cheng et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2021)
Pharmacokinetics and Pharmacodynamics of Insulin Tregopil in Relation to Premeal Dosing Time, Between Meal Interval, and Meal Composition in Patients With Type 2 Diabetes Mellitus
Anand Khedkar et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
A. J. Scheen
DIABETES & METABOLISM (2020)
Emerging Nano- and Micro-Technologies Used in the Treatment of Type-1 Diabetes
Rosita Primavera et al.
NANOMATERIALS (2020)
Enterically delivered insulin tregopil exhibits rapid absorption characteristics and a pharmacodynamic effect similar to human insulin in conscious dogs
Justin M. Gregory et al.
DIABETES OBESITY & METABOLISM (2019)
Impact of Insulin Tregopil and Its Permeation Enhancer on Pharmacokinetics of Metformin in Healthy Volunteers: Randomized, Open-Label, Placebo-Controlled, Crossover Study
Anand Khedkar et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery
Dale S. Edgerton et al.
JCI INSIGHT (2019)
The cell biology of systemic insulin function
Victoria L. Tokarz et al.
JOURNAL OF CELL BIOLOGY (2018)
MECHANISMS OF INSULIN ACTION AND INSULIN RESISTANCE
Max C. Petersen et al.
PHYSIOLOGICAL REVIEWS (2018)
Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial
Keith Bowering et al.
DIABETES CARE (2017)
A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives
Abdul Muheem et al.
SAUDI PHARMACEUTICAL JOURNAL (2016)
Intraperitoneal insulin infusion: treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia
P. R. van Dijk et al.
CLINICAL ENDOCRINOLOGY (2014)
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
Eun Yeong Choe et al.
DIABETES & METABOLISM JOURNAL (2014)
The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
Rodolfo Guardado-Mendoza et al.
ARCHIVES OF MEDICAL SCIENCE (2013)
Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review
J. Vora et al.
DIABETES OBESITY & METABOLISM (2013)
Clinical utility of insulin and insulin analogs
Ahter D. Sanlioglu et al.
ISLETS (2013)
Development of a Process to Manufacture PEGylated Orally Bioavailable Insulin
Partha Hazra et al.
BIOTECHNOLOGY PROGRESS (2010)
A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects
A. Khedkar et al.
DIABETES OBESITY & METABOLISM (2010)
The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes
S. D. Luzio et al.
DIABETES OBESITY & METABOLISM (2010)
Exploring patients’ perceptions for insulin therapy in type 2 diabetes: a Brazilian and Canadian qualitative study
C Guimaraes
Patient Preference and Adherence (2010)
Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic
Sam Maher et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
Fasting Versus Postload Plasma Glucose Concentration and the Risk for Future Type 2 Diabetes Results from the Botnia Study
Muhammad A. Abdul-Ghani et al.
DIABETES CARE (2009)
Target for Glycemic Control Concentrating on glucose
Louis Monnier et al.
DIABETES CARE (2009)
Insulin Therapy for Type 2 Diabetes
Sanne G. Swinnen et al.
DIABETES CARE (2009)
One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes
Muhammad A. Abdul-Ghani et al.
DIABETES CARE (2008)
Process and purification for manufacture of a modified insulin intended for oral delivery
Nitesh Dave et al.
JOURNAL OF CHROMATOGRAPHY A (2008)
Insulin-associated weight gain in diabetes - causes, effects and coping strategies
David Russell-Jones et al.
DIABETES OBESITY & METABOLISM (2007)
The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes
Louis Monnier et al.
DIABETES CARE (2007)
Reproducibility and variability in the action of injected insulin
H Gin et al.
DIABETES & METABOLISM (2005)
Dose-response effect of a single administration of oral hexyl-insulin to monoconjugate 2 in healthy nondiabetic subjects
E Wajcberg et al.
DIABETES CARE (2004)
Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: Results from a phase I/II clinical trial
S Clement et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2004)
Clinical significance, pathogenesis, and management of postprandial hyperglycemia
JE Gerich
ARCHIVES OF INTERNAL MEDICINE (2003)
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients -: Variations with increasing levels of HbA1c
L Monnier et al.
DIABETES CARE (2003)
Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes
M Kipnes et al.
DIABETES CARE (2003)
One or two hours postprandial glucose measurements: Are they the same?
E Sivan et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2001)
分享论文
